Regulatory Affairs Pharma
New Rules in China Tighten ADR Reporting Environment
July 2011
This article discusses the new reporting rules on adverse drug reactions.
This article appears in the July issue of Regulatory Affairs Pharma.
Capabilities
Suggested News & Insights
Digital Health Transformation: A Practical Guide for Life Sciences CompaniesJanuary 18, 20232023 — The Year “Modernization” Comes to the U.S. Cosmetics IndustryJanuary 5, 2023U.S. Oversight Agencies Identify Program Integrity Risks Related to Increased Telehealth Usage During the PandemicDecember 13, 2022Switzerland Will Open Its Market for U.S. Food & Drug Administration (FDA) - Regulated Medical DevicesDecember 7, 2022One Step Forward, Two Steps Back: FDA’s Final Guidance on Clinical Decision Software Raises More Questions Than AnswersOctober 26, 2022New Swiss Data Protection Act – And a New Swiss-U.S. Trans-Atlantic Data Privacy Framework?October 25, 2022
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory